Corporate Finance, DeFi, Blockchain, Web3 News
Fintech, DeFi, Blockchain, Web3 Daily News by Finyear

Santhera nomme Christoph Rentsch directeur financier

La société pharmaceutique Santhera a nommé Christoph Rentsch au poste de directeur financier (CFO). Il prendra ses fonctions le 1er juillet et entrera parallèlement à la direction, a-t-elle indiqué lundi.

Christoph Rentsch dispose d'une large expérience dans le secteur de la pharma et de la biopharma, souligne le communiqué. Après avoir travaillé à ses débuts chez Credit Suisse, il a oeuvré ensuite notamment pour Lonza, Roche et la société pharmaceutique en mains privées Polyphor.

Communiqué original :

Fin janvier, Santhera avait déjà procédé à une nomination au sein de sa direction, avec l'arrivée du directeur opérationnel (COO) Giovanni Stropoli.

Santhera Appoints Chief Financial Officer

Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Christoph Rentsch as Chief Financial Officer.

With effect from July 1, 2015, the Santhera Board of Directors appoints Christoph Rentsch as CFO and member of the Executive Management Team headed by Chief Executive Officer Thomas Meier, PhD.

Christoph Rentsch started his career in investment banking at Credit Suisse. Subsequently, he worked for Lonza both in Switzerland and the US. Thereafter he joined Roche as Head of Group Funding and Capital Markets for several years before he became partner of Caperis Ltd, an investment advisory and management firm. Since 2010 he served as CFO of privately-held Polyphor, where he led several financing rounds and supported the company in key stages of its development. Christoph Rentsch holds a degree in economics and business administration from the University of Applied Sciences, Basel.

"Christoph Rentsch brings extensive financial, strategic, and operational expertise to Santhera that will further strengthen the management team," said Martin Gertsch, Chairman of the Santhera Board of Directors. "His appointment reflects the growth potential we foresee for Santhera. We are delighted he will be part of the leadership team as we move forward."

"This is an exciting time for Santhera," added Christoph Rentsch. "As the company transitions from a development-stage to a product company, I am looking forward to working with the Executive Management Team and contributing to a successful implementation of the company's growth strategy."

"I am very pleased to welcome Christoph to the Executive Management Team," commented Thomas Meier, PhD, CEO of Santhera. "With his background in the biotech/pharma sector, he will contribute the financial expertise which we need now to implement our commercial operations plans and to build the product pipeline in the future."

Further information on Santhera's Executive Management is available on the Company's website.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Raxone®/Catena® as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital Muscular Dystrophies (CMD), all areas of high unmet medical need for which no therapies are currently available.

Les médias du groupe Finyear

Jeudi 25 Juin 2015